A Study of DII235 in Adults With Elevated Lipoprotein(a)

Last Update: Dec 12, 2025

A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-finding Study to Evaluate Efficacy, Safety, and Tolerability of DII235 in Adults With Elevated Lipoprotein(a)

ClinicalTrials.gov Identifier:

NCT07235046

Novartis Reference Number:CDII235A12201

See if you Pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

The main purpose of this study is to determine the safety and efficacy of DII235 in adults with elevated lipoprotein(a).

Condition

Lipoprotein Disorder

Phase

Phase2

Overall Status

Recruiting

Number of Participants

200

Start Date

Dec 02, 2025

Completion Date

Sep 08, 2028

Gender

All

Age(s)

18 Years - 80 Years (Adult, Older Adult)

Interventions

Drug

DII235

Solution for injection

Drug

Saline

solution for injection

Eligibility Criteria

Inclusion Criteria:

* Signed informed consent must be obtained prior to participation in the study.
* Male or female participants 18 to 80 years of age (inclusive) at the screening.
* Lp(a) ≥ 150 nmol/L at screening, measured at the central laboratory.
* Participants with evidence of atherosclerotic cardiovascular disease and/or type 2 diabetes mellitus.

Exclusion Criteria:

* Severe renal dysfunction
* Hepatic dysfunction
* Malignancy within the last 5 years
* Use of investigational medications as defined in the protocol
* History or presence at screening of an underlying disease, or surgical, physical, medical, or psychiatric condition that, in the opinion of the Investigator, or sponsor if consulted, would potentially affect participant safety within the study or interfere with participating in or completing the study or with the interpretation of data

Other protocol-defined inclusion/exclusion criteria may apply